Figure 3. Overall survival and recurrence-free survival of patients in the training cohort.

A. and the validation cohort B. were stratified by positive/negative baseline serum CA125 levels. The cut-off value of serum CA125 for predicting pancreatic cancer metastasis was identified as 18.4 U/mL. In patients with a decrease in postoperative serum CA19-9, postoperative serum CA125 decrease/non-decrease further distinguished overall survival and recurrence-free survival in both the training cohort C. and the validation cohort D.